ClinicalTrials.gg
CompletedNCT05134350Updated Jan 10, 2025Results posted

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

A Phase 1 interventional study of LOXO-305 and Omeprazole in Healthy Volunteers, sponsored by Loxo Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Feb 2020, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of non-.
  • Within (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m²).
  • Participants will be in good general health, based on medical history, physical examination findings, vital signs, 12 lead (ECG), or clinical laboratory tests, as determined by the Investigator (or designee).
  • Able to comply with all study procedures, including the 25-night stay at the Clinical Research Unit and follow-up phone call.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:

    • liver disease
    • pancreatitis
    • peptic ulcer disease
    • intestinal malabsorption
    • gastric reduction surgery
    • history or presence of clinically significant cardiovascular disease.
  • Participants with out-of-range, at-rest vital signs.
  • Abnormal laboratory values determined to be clinically significant by the Investigator (or designee), and Sponsor.
  • Clinically significant abnormality, as determined by the Investigator (or designee), from physical examination.
  • Participation in any other study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to the first dose administration (Day 1).
  • Use or intention to use any prescription or over-the-counter medications within 14 days prior to the first dose administration (Day 1) through the end of the trial.
  • History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.
  • Donation of blood from 56 days prior to Screening, plasma or from 4 weeks prior to Screening.
  • Receipt of blood products within 2 months prior to Check-in (Day -1).
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), GI, neurological, or psychiatric disorder (as determined by the Investigator), or cancer within the past 5 years (except localized basal cell, squamous, or in situ cancer of the skin).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: ABC

    * Period 1: Single oral dose of 200 milligram (mg) LOXO-305 (Fasted state) on Day 1 (Treatment A) * Period 2: Single oral dose of 200 mg LOXO-305 (Fed state) on Day 8 (Treatment B) * Period 3: Single oral dose of 40 mg Omeprazole (Fasted state) on Day 15 to 17 and single oral dose of 200 mg LOXO-305 + 40 mg Omeprazole (Fasted state) on Day 18 (Treatment C) A washout period of 7 days was maintained between each treatment period.

    Drug: LOXO-305 · Drug: Omeprazole

  • Experimental
    Treatment Sequence 2: BAC

    * Period 1: Single oral dose of 200 mg LOXO-305 (Fed state) on Day 1 (Treatment B) * Period 2: Single oral dose of 200 mg LOXO-305 (Fasted state) on Day 8 (Treatment A) * Period 3: Single oral dose of 40 mg Omeprazole (Fasted state) on Day 15 to 17 and single oral dose of 200 mg LOXO-305 + 40 mg Omeprazole (Fasted state) on Day 18 (Treatment C) A washout period of 7 days was maintained between each treatment period.

    Drug: LOXO-305 · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305

    PK: AUC(0-24) hours of LOXO-305 is reported. AUC(0-24) was calculated by the linear trapezoidal method.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post LOXO-305 dose

  2. PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-305

    PK: AUC(0-t) of LOXO-305 is reported. AUC(0-t) was calculated by linear trapezoidal method.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  3. PK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-305

    PK: AUC(0-inf) of LOXO-305 is reported. AUC(0-inf) was calculated using the formula: AUC(0-inf) = AUC(0-t) + Ct/λZ; where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  4. PK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-305

    PK: %AUCextrap of LOXO-305 is reported.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  5. PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305

    PK: Cmax of LOXO-305 is reported.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  6. PK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-305

    PK: tmax of LOXO-305 is reported.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  7. PK: Apparent Terminal Elimination Half-life (t½) of LOXO-305

    PK: t½ of LOXO-305 is reported.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

  8. PK: Apparent Systemic Clearance (CL/F) of LOXO-305

    PK: CL/F of LOXO-305 is reported.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose

07

Results

Posted Jan 10, 2025

Participant flow

Participants were randomized to 2 treatment sequences (ABC and BAC), with each sequence having 3 periods where participants were crossed over between the periods in each sequence. A washout period of 7 days was maintained between each treatment period.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BAC
Started55
Received at least 1 dose of study drug55
Completed55
Not completed00
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BAC
Started55
Completed55
Not completed00
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: BAC
Started55
Completed55
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305

PK: AUC(0-24) hours of LOXO-305 is reported. AUC(0-24) was calculated by the linear trapezoidal method.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post LOXO-305 dose
Reported as:
Geometric mean · hour*nanograms per milliliter
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305
hour*nanograms per milliliterTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-30555100 ± 17.551900 ± 12.859900 ± 15.5
PrimaryPK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-305

PK: AUC(0-t) of LOXO-305 is reported. AUC(0-t) was calculated by linear trapezoidal method.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Geometric mean · hour*nanograms per milliliter
PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-305
hour*nanograms per milliliterTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of LOXO-30589400 ± 17.885100 ± 19.399600 ± 17.1
PrimaryPK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-305

PK: AUC(0-inf) of LOXO-305 is reported. AUC(0-inf) was calculated using the formula: AUC(0-inf) = AUC(0-t) + Ct/λZ; where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Geometric mean · hour*nanograms per milliliter
PK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-305
hour*nanograms per milliliterTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC[0-Inf]) of LOXO-30590200 ± 17.686100 ± 18.9101000 ± 16.8
PrimaryPK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-305

PK: %AUCextrap of LOXO-305 is reported.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Geometric mean · percentage of extrapolation
PK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-305
percentage of extrapolationTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Percentage Extrapolation for AUC0-Inf (%AUCextrap) of LOXO-3050.911 ± 27.21.12 ± 42.60.893 ± 34.5
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305

PK: Cmax of LOXO-305 is reported.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Geometric mean · nanograms per milliliter
PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305
nanograms per milliliterTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-3055450 ± 31.74340 ± 16.65490 ± 16.7
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-305

PK: tmax of LOXO-305 is reported.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-305
hoursTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of LOXO-3052.50 (1.50 to 4.00)3.00 (1.00 to 4.00)2.25 (1.50 to 3.00)
PrimaryPK: Apparent Terminal Elimination Half-life (t½) of LOXO-305

PK: t½ of LOXO-305 is reported.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Mean · hours
PK: Apparent Terminal Elimination Half-life (t½) of LOXO-305
hoursTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Apparent Terminal Elimination Half-life (t½) of LOXO-30520.2 ± 4.2421.5 ± 5.7519.7 ± 2.87
PrimaryPK: Apparent Systemic Clearance (CL/F) of LOXO-305

PK: CL/F of LOXO-305 is reported.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post LOXO-305 dose
Reported as:
Geometric mean · Liter per Hours (L/h)
PK: Apparent Systemic Clearance (CL/F) of LOXO-305
Liter per Hours (L/h)Treatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)
PK: Apparent Systemic Clearance (CL/F) of LOXO-3052.22 ± 17.62.32 ± 18.91.99 ± 16.8

Adverse events

Collected over Day 1 up to Day 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: 200 mg LOXO-305 (Fasted)0/10 (0%)0/10 (0%)0/10 (0%)
Treatment B: 200 mg LOXO-305 (Fed)0/10 (0%)0/10 (0%)1/10 (10%)
Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)0/10 (0%)0/10 (0%)0/10 (0%)
Treatment C: 40 mg Omeprazole (Fasted)0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
EventTreatment A: 200 mg LOXO-305 (Fasted)Treatment B: 200 mg LOXO-305 (Fed)Treatment C: 200 mg LOXO-305 + 40 mg Omeprazole (Fasted)Treatment C: 40 mg Omeprazole (Fasted)
NauseaGastrointestinal disorders0/101/100/100/10
VomitingGastrointestinal disorders0/101/100/100/10
HeadacheNervous system disorders0/101/100/100/10

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: ABCTreatment Sequence 2: BACTotal
Mean43.2 ± 10.6635.2 ± 4.8739.2 ± 8.88
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: ABCTreatment Sequence 2: BACTotal
Female123
Male437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: ABCTreatment Sequence 2: BACTotal
Hispanic or Latino336
Not Hispanic or Latino224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: ABCTreatment Sequence 2: BACTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White448
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence 1: ABCTreatment Sequence 2: BACTotal
United States5510
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Mar 2020, 1 month.

Results were first posted in Jan 2025, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 24, 2021
StartActual
Feb 6, 2020
Primary completionActual
Mar 23, 2020
CompletionActual
Mar 23, 2020
Results first posted
Jan 10, 2025
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05134350
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Feb 6, 2020
Primary completion
Mar 23, 2020
Completion
Mar 23, 2020
Results posted
Jan 10, 2025
Last update
Jan 10, 2025

Study contacts

Renée Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion